ArticleEuropean journal of nuclear medicine and molecular imaging2026
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the detectability of residual tumor-involved lymph nodes (LNs) using
methodsThis retrospective study analyzed 161 ESCC patients who received esophagectomy following NICT. All patients underwent preoperative
resultsFor overall lymph node analysis, there was no significant difference in diagnostic performance between the optimal PET parameter, total lesion glycolysis (TLG), and the best CECT parameter, short-axis diameter (SAD) (AUC: 0.830 vs. 0.797, P = 0.08). Nevertheless, a combined model incorporating TLG and SAD of PET/CT demonstrated significantly superior diagnostic performance compared to SAD of CECT (AUC: 0.863 vs. 0.797, P < 0.001). In subregional analyses, TLG performed best in the paraesophageal group and abdominal area, with AUCs of 0.824 and 0.857. The SUVmax ratio of lymph nodes to liver blood pool (LLR) demonstrated the highest diagnostic performance in the recurrent nerve group and subcarinal area, with AUCs of 0.885 and 0.884, respectively.
conclusion
Indexed as
Identifiers
41091187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.